EXPERIMENTAL AND CLINICAL EPILEPTOLOGY

This article reviews the issues of experimental and clinical epileptology. For the development and implementation of new medications and technologies of medicinal interventions, as well as investigation of main “targets” for anti-epileptic drugs, it is necessary to develop the experimental models of various forms of epilepsy and epileptic seizures. To this end, we studied the alterations of cerebral electrical activity in rats with chronic cobalt epileptogenic focus which represents an optimal experimental model of epileptic state. The significance of hypothalamus was shown to be the lead (determinate) structure within the pathologic epileptic system during formation of secondary generalized seizures. The drug” targets” and possibilities for combined administration of anticonvulsants and antioxidants have been revealed. Pharmaco-genetic investigations enable us to predict the effects of different antiepileptic drugs

EXPERIENCE OF USING LAKOSAMID IN VARIOUS FORMS OF EPILEPSY (The results of observational study in city outpatient health care chain of Moscow)

This paper presents experience of using Vimpat in outpatient health care chain of Moscow. In the observational study were attended 49 patients with difficult for treatment focal forms of epilepsy (cryptogenic and symptomatic forms). Vimpat used in complex therapy in the mean effective dose of 300-400 mg per day. As a result, the data on a cohort of Russian patients showed that Vimpat demonstrate a sufficiently high clinical efficacy (55%, p<0.01) and appropriate for use in patients with difficult for treatment forms of epilepsy in complex therapy when the previous treatment was ineffective

EXPERIENCE OF TREATMENT WITH GENERIC LAMOTRIDJIN IN DIFFERENT FORMS OF EPILEPSY (The results of focus observation in out-patient clinics network of Moscow city public healthcare services)

Focused observational study on efficacy, tolerability and quality of life in adult patients with different forms of epilepsy taking combined therapy with lamotrigine (Sazar). 32 patients (19 men and 13 women), 23-79 years old with focal forms (cryptogenic and symptomatic) epilepsy with different disease duration and presence of of different type and etiology seizures were enrolled into the study. Patients having been taken various antiepileptic drugs in monotherapy with different efficacy degree were observed. Patients sample included 20 patients, receiving valproic acid in various dosages and 12 patients, receiving topiramate. Sazar was added as a second drug with initial dosage of 25 mg daily. Results of focused observation allow us to make conclusion of possible expedience of Sazar indication, especially in patients in whom therapy with valproic acid is less effective